Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the Indianapolis pharmaceutical company.

WeightWatchers has announced a new partnership with Eli Lilly's LillyDirect ... will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers ...

The company announced a new partnership with Eli Lilly’s LillyDirect pharmacy ... to receive prescriptions for Zepbound in single-dose vial form directly through the WeightWatchers app, which ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers ... Our innovative, trusted spectrum of solutions provides members ...

(Reuters) -Eli Lilly on Thursday downplayed ... slightly below analysts' expectations of $2.33 billion. Lilly in February cut the price for vials of Zepbound by $50 or more and expanded the ...